Teva- Pharmaceutical Industries Ltd. ADR (TEVA) concluded trading on Wednesday at a closing price of $18.41, with 4.29 million shares of worth about $79.02 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 41.51% during that period and on October 23, 2024 the price saw a gain of about 0.16%. Currently the company’s common shares owned by public are about 1.13B shares, out of which, 1.13B shares are available for trading.
Stock saw a price change of 2.16% in past 5 days and over the past one month there was a price change of 3.84%. Year-to-date (YTD), TEVA shares are showing a performance of 76.34% which increased to 125.06% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $8.06 but also hit the highest price of $19.08 during that period. The average intraday trading volume for Teva- Pharmaceutical Industries Ltd. ADR shares is 7.51 million. The stock is currently trading 3.80% above its 20-day simple moving average (SMA20), while that difference is up 2.26% for SMA50 and it goes to 18.56% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) currently have 1.13B outstanding shares and institutions hold larger chunk of about 54.45% of that.
The stock has a current market capitalization of $20.86B and its 3Y-monthly beta is at 0.87. It has posted earnings per share of -$0.39 in the same period. It has Quick Ratio of 0.59 while making debt-to-equity ratio of 2.98. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TEVA, volatility over the week remained 1.97% while standing at 2.20% over the month.
Stock’s fiscal year EPS is expected to drop by -4.19% while it is estimated to increase by 13.93% in next year. EPS is likely to shrink at an annualized rate of 0.47% for next 5-years, compared to annual growth of 26.63% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Argus on July 10, 2024 offering a Buy rating for the stock and assigned a target price of $20 to it. Coverage by JP Morgan stated Teva- Pharmaceutical Industries Ltd. ADR (TEVA) stock as a Neutral in their note to investors on March 08, 2024, suggesting a price target of $14 for the stock. On February 12, 2024, Piper Sandler Upgrade their recommendations, while on January 23, 2024, Jefferies Upgrade their ratings for the stock with a price target of $14. Stock get a Neutral rating from Piper Sandler on January 03, 2024.
